Defects in homologous recombination repair can occur through numerous mechanisms including the loss of BRCA1 and BRCA2 function within the breast cancer, thus resulting in a gBRCAm-like phenotype12, which could potentially be treated with PARP inhibitors. The gene discussed is BRCA1; the disease is breast carcinoma.